


Japan's Shionogi joins World Economic Forum and signs Davos Compact on Antimicrobial Resistance

May 1, 2026 | News

Shionogi will further strengthen its efforts to address AMR



Japan-based Shionogi & Co. has joined the World Economic Forum (WEF), and signed the Davos Compact on Antimicrobial Resistance (AMR).

The World Economic Forum, established in 1971 and headquartered in Switzerland, is an independent international organisation committed to improving the state of the world. It engages leaders from business, government, academia, and civil society to shape global, regional, and industry agendas. The Forum provides platforms for dialogue on critical global issues, including through its Annual Meeting in Davos and various public-private partnership initiatives across sectors.

By joining the World Economic Forum, Shionogi will participate in the Health and Healthcare Centre, one of the Forum's collaborative platforms. Through engagement and dialogue with global public- and private-sector leaders, Shionogi will communicate its perspectives and positions, while appropriately incorporating global healthcare trends and policy developments gained through these interactions into the Group's business strategy and operations.

In conjunction with joining the Forum, Shionogi has also signed the Davos Compact on AMR. The Compact was developed by the World Economic Forum's Global Future Council on AMR in response to the Political Declaration on AMR adopted at the United Nations General Assembly High-Level Meeting in 2024. It aims to save more than 100 million lives by significantly reducing deaths attributable to AMR by 2050.

Through its participation in the Forum and its commitment to the Compact, Shionogi will further strengthen its efforts to address AMR, working in collaboration with stakeholders in Japan and globally to contribute to sustainable and effective solutions.

Shionogi has identified "Protecting people from the threat of infectious diseases" as one of its key material issues, and is advancing initiatives to deliver comprehensive care for infectious diseases. The company will continue to play a responsible role across the entire value chain—including research and development, manufacturing, supply, and appropriate use—in addressing the global challenge of antimicrobial resistance.